A Phase 3 interventional study of Acalabrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Completed at 155 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 4th largest by enrollment, is one of 4 that started in 2015, is one of 9 in phase 3, and was the 4th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
Zulfa Omer · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Seema Bhat · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 9 · Phase 4 1
First in 2014; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 535 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 61 across the 39 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca: 6 open now, 21 under way, 5 of them phase 3. Of 18 finished, 10 (56%) have results posted.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 4th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2015, is one of 7 in phase 3, and was the 13th registered.
AstraZeneca’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2005.
9 of the studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT05971251University of Alabama at BirminghamAddition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | 2026-12-31 |
| NCT06757647Seema BhatAcalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 2026-12-31 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AstraZeneca’s 42 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria.
2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Tine to next treatment (TTNT); Overall Survival (OS)
ELEVATE-TN is a global, phase 3, multicenter, open-label study in patients with treatment-naive chronic lymphocytic leukemia (CLL). Study enrollment is completed. The study randomized a total of 535 subjects in 142 study sites in 18 countries between 14 September 2015 through 08 February 2017. Patients were randomly assigned to receive Acalabrutinib and Obinutuzumab, Acalabrutinib monotherapy, or Obinutuzumab and oral Chlorambucil. The primary endpoint was progression-free survival between the two combination-therapy groups, defined as the time from randomization until disease progression by use of iwCLL 2008 criteria, or death, assessed by independent review committee (IRC). Crossover to Acalabrutinib was allowed in patients who progressed on Obinutuzumab-Chlorambucil.
The results of this study provide new evidence for therapy in patients with treatment-naive chronic lymphocytic leukemia by showing the efficacy of Acalabrutinib used with or without Obinutuzumab compared with chemoimmunotherapy.
Currently the study is in maintenance phase, with more than 430 subjects on study, to generate more evidence. We are not expecting any significant change in the near future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Men and women:
a. ≥ 65 years of age OR b. > 18 and \< 65 years of age, provided that they meet at least one of the following criteria: i. 30 to 69 mL/min using the Cockcroft-Gault equation ii. A score higher than 6 on the CIRS-G (Appendix L).
Diagnosis of CD20+ CLL that meets published diagnostic criteria (Hallek 2008):
Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment:
i. Unintentional weight loss ≥ 10% within the previous 6 months before Screening.
ii. Significant fatigue (i.e., ECOG performance status 2; inability to work or perform usual activities).
iii. Fevers higher than 100.5°F or 38.0°C for 2 or more weeks before Screening without evidence of infection.
iv. Night sweats for > 1 month before Screening without evidence of infection.
Meet the following laboratory parameters:
Exclusion Criteria:
History of prior except for the following:
14. Serologic status reflecting active or C infection. Subjects with hepatitis B core antibody positive who are surface antigen negative or who are antibody positive will need to have a negative PCR result before randomization. Those who are hepatitis B surface antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive will be excluded.
15. History of stroke or intracranial hemorrhage within 6 months before randomization.
16. Known history of a bleeding diathesis (e.g., hemophilia, von Willebrand disease).
17. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 7 days of first dose of study drug.
18. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
19. Breast feeding or pregnant. 20. Current life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the subject's safety or put the study at risk.
21. Concurrent participation in another therapeutic clinical trial. 22. Requires treatment with a strong inhibitor/inducer. 23. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 1 Day 1. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
Drug: Obinutuzumab · Drug: Chlorambucil
Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles starting at Cycle 2 Day 1. Acalabrutinib (ACP-196) will be orally administered starting on Cycle 1 Day 1. Daily administration of Acalabrutinib (ACP-196) will continue until disease progression or unacceptable toxicity.
Drug: Acalabrutinib · Drug: Obinutuzumab
Acalabrutinib (ACP-196) will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
Drug: Acalabrutinib
Also known as: ACP-196 (Calquence)
Also known as: GAZYVA / GAZYVARO
Also known as: LEUKERAN
Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B
To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.
Time frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Progression-free Survival by IRC Assessment Arm A Versus Arm C
To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib monotherapy (Arm C) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.
Time frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C
ORR was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, or PR at or before initiation of subsequent anticancer therapy. ORR including PRL was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, PR or PRL at or before initiation of subsequent anticancer therapy
Time frame: IRC assessments were done from randomization date until disease progression or death or IRC discontinuation date on 08Feb2019 (as the IA based on this data cutoff date showed the study crossing superiority boundary) whichever comes first up to 40 months.
Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C
TTNT was defined as the time from randomization to start date of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first. TTNT was analyzed in the same fashion as that for the primary efficacy analysis
Time frame: From randomization date to start of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first assessed up to 40 months of follow-up.
Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C
OS was defined as the time from the date of randomization to death due to any cause.
Time frame: From randomization date until death, withdrawal by subject, lost to follow-up, or by analysis data cut off date on 08Feb2019 whichever comes first up to 40 months of follow-up.
A randomized, multicenter, open-label, 3 arm phase 3 study of Obinutuzumab in combination with Chlorambucil (Chlb+Obin), Acalabrutinib in combination with Obinutuzumab (Acala+Obin), and Acalabrutinib monotherapy (Acala) in subjects with previously untreated chronic lymphocytic leukemia. A total of 535 subjects recruited from 142 sites in 18 countries were randomized (1:1:1) as follows: 179/179 /177 subjects in Acla+Obin arm / Acala arm / Chlb+Obin arm respectively.
| Milestone | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm B: Acalabrutinib in Combination With Obinutuzumab | Arm C: Acalabrutinib Monotherapy |
|---|---|---|---|
| Started | 177 | 179 | 179 |
| Crossed over from arm a to arm c | 45 | 0 | 0 |
| Completed | 145 | 0 | 0 |
| Not completed | 32 | 179 | 179 |
| Withdrew: Death | 16 | 6 | 9 |
| Withdrew: Physician decision | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 12 | 6 | 9 |
| Withdrew: Lost to follow-up | 2 | 1 | 3 |
| Withdrew: Ongoing in study | 0 | 163 | 157 |
| Withdrew: Reasons other than above listed | 2 | 0 | 0 |
To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.
| Months | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm B: Acalabrutinib in Combination With Obinutuzumab |
|---|---|---|
| Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B | 22.6 (20.2 to 27.8) | NA (NA to NA) |
To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib monotherapy (Arm C) based on IRC assessment of progression-free survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia criteria (IWCLL; Hallek et al. 2008) with incorporation of the clarification for treatment-related lymphocytosis (Cheson et al. 2012), hereafter referred to as IWCLL 2008 criteria, in subjects with previously untreated CLL. PFS, defined as the time from date of randomization to the date of first IRC-assessed disease progression or death due to any cause, whichever comes first.
| Months | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm C: Acalabrutinib Monotherapy |
|---|---|---|
| Progression-free Survival by IRC Assessment Arm A Versus Arm C | 22.6 (20.2 to 27.6) | NA (34.2 to NA) |
ORR was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, or PR at or before initiation of subsequent anticancer therapy. ORR including PRL was defined as the proportion of subjects who achieved a best response of CR, CRi, nPR, PR or PRL at or before initiation of subsequent anticancer therapy
| percentage of participants | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm B: Acalabrutinib in Combination With Obinutuzumab | Arm C: Acalabrutinib Monotherapy |
|---|---|---|---|
| IRC-assessed Objective Response Rate (ORR) in Arm A Versus Arm B and Arm A Versus Arm C | 78.5 (71.9 to 83.9) | 93.9 (89.3 to 96.5) | 85.5 (79.6 to 89.9) |
TTNT was defined as the time from randomization to start date of non-protocol specified subsequent anticancer therapy for CLL or death due to any cause, whichever came first. TTNT was analyzed in the same fashion as that for the primary efficacy analysis
| Months | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm B: Acalabrutinib in Combination With Obinutuzumab | Arm C: Acalabrutinib Monotherapy |
|---|---|---|---|
| Time to Next Treatment (TTNT) in Arm A Versus Arm B and Arm A Versus Arm C | NA (28.9 to NA) | NA (NA to NA) | NA (NA to NA) |
OS was defined as the time from the date of randomization to death due to any cause.
| Months | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm B: Acalabrutinib in Combination With Obinutuzumab | Arm C: Acalabrutinib Monotherapy |
|---|---|---|---|
| Overall Survival (OS) in Arm A Versus Arm B and Arm A Versus Arm C | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over All adverse events were reported from randomization date until 30 days after the last dose of study drug or the start of new anticancer therapy (whichever comes first) up to 61 months. After this period, investigators reported SAEs or other AEs of concern that are believed to be related to prior treatment with study drug up to 5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Obinutuzumab in Combination With Chlorambucil | 17/177 (9.6%) | 37/169 (21.9%) | 167/169 (98.8%) |
| Arm B: Acalabrutinib in Combination With Obinutuzumab | 9/179 (5%) | 69/178 (38.8%) | 171/178 (96.1%) |
| Arm C: Acalabrutinib Monotherapy | 11/179 (6.1%) | 57/179 (31.8%) | 170/179 (95%) |
| Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy | 2/45 (4.4%) | 6/45 (13.3%) | 37/45 (82.2%) |
| Event | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm B: Acalabrutinib in Combination With Obinutuzumab | Arm C: Acalabrutinib Monotherapy | Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 3/169 | 12/178 | 5/179 | 0/45 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 8/169 | 1/178 | 0/179 | 0/45 |
| Febrile neutropeniaBlood and lymphatic system disorders | 7/169 | 3/178 | 2/179 | 1/45 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/169 | 4/178 | 0/179 | 0/45 |
| AnaemiaBlood and lymphatic system disorders | 0/169 | 3/178 | 4/179 | 0/45 |
| Acute myocardial infarctionCardiac disorders | 1/169 | 1/178 | 3/179 | 1/45 |
| Upper respiratory tract infectionInfections and infestations | 1/169 | 0/178 | 0/179 | 1/45 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/169 | 1/178 | 0/179 | 1/45 |
| NauseaGastrointestinal disorders | 0/169 | 0/178 | 0/179 | 1/45 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/169 | 0/178 | 0/179 | 1/45 |
| Event | Arm A: Obinutuzumab in Combination With Chlorambucil | Arm B: Acalabrutinib in Combination With Obinutuzumab | Arm C: Acalabrutinib Monotherapy | Arm A Cross-over: Obinutuzumab+Chlorambucil Crossover to Acalabrutinib Monotherapy |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 76/169 | 56/178 | 19/179 | 1/45 |
| HeadacheNervous system disorders | 20/169 | 71/178 | 66/179 | 10/45 |
| Infusion related reactionInjury, poisoning and procedural complications | 67/169 | 24/178 | 0/179 | 1/45 |
| DiarrhoeaGastrointestinal disorders | 36/169 | 69/178 | 62/179 | 8/45 |
| NauseaGastrointestinal disorders | 53/169 | 36/178 | 40/179 | 9/45 |
| FatigueGeneral disorders | 29/169 | 50/178 | 33/179 | 6/45 |
| ContusionInjury, poisoning and procedural complications | 7/169 | 42/178 | 27/179 | 5/45 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/169 | 39/178 | 28/179 | 3/45 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/169 | 39/178 | 33/179 | 7/45 |
| Upper respiratory tract infectionInfections and infestations | 14/169 | 38/178 | 33/179 | 6/45 |
Analysis was performed on intent-to-treat (ITT) population, which included all randomized participants grouped according to assigned treatment.
| Age, Categorical(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 35 | 28 | 87 |
| >=65 years | 153 | 144 | 151 | 448 |
| Sex: Female, Male(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| Female | 71 | 68 | 68 | 207 |
| Male | 106 | 111 | 111 | 328 |
| Ethnicity (NIH/OMB)(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 11 | 2 | 11 | 24 |
| Not Hispanic or Latino | 156 | 169 | 156 | 481 |
| Unknown or Not Reported | 10 | 8 | 12 | 30 |
| Race (NIH/OMB)(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 4 | 5 | 4 | 13 |
| White | 165 | 164 | 170 | 499 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 7 | 5 | 18 |
| Region of Enrollment(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| Belgium | 5 | 5 | 3 | 13 |
| France | 3 | 3 | 1 | 7 |
| Germany | 3 | 1 | 3 | 7 |
| Italy | 11 | 9 | 5 | 25 |
| Spain | 7 | 3 | 3 | 13 |
| Sweden | 1 | 3 | 3 | 7 |
| United Kingdom | 12 | 16 | 17 | 45 |
| Brazil | 4 | 5 | 5 | 14 |
| Chile | 2 | 0 | 3 | 5 |
| Colombia | 1 | 0 | 0 | 1 |
| Canada | 7 | 8 | 7 | 22 |
| United States | 54 | 56 | 63 | 173 |
| Hungary | 17 | 26 | 15 | 58 |
| Lithuania | 9 | 2 | 6 | 17 |
| Poland | 14 | 20 | 25 | 59 |
| Australia | 9 | 9 | 8 | 26 |
| New Zealand | 8 | 4 | 5 | 17 |
| Israel | 10 | 9 | 7 | 26 |
| IXRS Randomization Stratification Factor: Presence of 17p Deletion(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| Yes | 17 | 21 | 19 | 57 |
| No | 160 | 158 | 160 | 478 |
| IXRS Randomization Stratification Factor: ECOG Performance Status(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| 0-1 (0=Fully Active; 1 =Restricted in Physically Strenuous Activity) | 168 | 169 | 167 | 504 |
| 2 (2=Ambulatory and capable of all selfcare but unable to carry out any work activities) | 9 | 10 | 12 | 31 |
| IXRS Randomization Stratification Factor: Geographic Region(Participants) | Obinutuzumab in Combination With Chlorambucil | Acalabrutinib in Combination With Obinutuzumab | Acalabrutinib Monotherapy | Total |
|---|---|---|---|---|
| North America and West Europe | 103 | 104 | 105 | 312 |
| Other | 74 | 75 | 74 | 223 |
Showing the first 100 of 155 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2015 to primary completion in Feb 2019, 43 months.
Results were first posted in Jan 2023, 3 years 11 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 43 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acalabrutinib · Obinutuzumab
Leukemia, Lymphocytic, Chronic, B-Cell →